Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Arcturus Therapeutics (ARCT) Tops Q1 EPS by 338c
May 9, 2022 5:04 PM EDTArcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.94, $3.38 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $5.24 million versus the consensus estimate of $6.3 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
... More


